Abdul Mannan Inside the Diagnostic Maze of Atypical CML
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”It’s rare. It’s aggressive. It mimics other blood cancers.
No Philadelphia chromosome. No targeted therapy. Just tough decisions.
Diagnosis needs sharp eyes. Dysplastic cells. High white counts. Molecular clues.
SETBP1 and ASXL1 mutations tell the story.
CSF3R points elsewhere.
Median survival? 14-30 months without transplant.
But here’s hope: Early recognition matters. Molecular testing guides us. Transplant can cure selected patients.
Every rare diagnosis teaches us something profound about blood biology.
As haematologists, we don’t just treat diseases. We solve puzzles that save lives.
What rare condition taught you the most?”
Keep up with Hemostasis Today.
-
Nov 8, 2025, 05:31Phenotyping of Human Platelets by Daisie Yates
-
Nov 8, 2025, 04:35Inaugural Women In Hematology US Focus Meeting 2025 Officially Commenced
-
Nov 8, 2025, 01:40Mikhail Fominykh: What I Read This Week
-
Nov 8, 2025, 01:40Shubham Khandve: Cell and Gene Therapy is No Longer the Future
-
Nov 8, 2025, 01:39World Federation of Hemophilia: Hemophilia Care is Evolving
-
Nov 8, 2025, 01:38Muhammad Awidi – Choking Growth One Puff at a Time: How Tobacco is Strangling Jordan’s Economy
-
Nov 8, 2025, 01:37Steven Murphy Discusses Peptides in Orthobiologic Medicine at AMSKU 2025
-
Nov 8, 2025, 01:37Cellfie of the Day: Classic Gaucher Cells Under the Microscope
-
Nov 8, 2025, 01:36Krishna Aragam and Team Identify CD36 Variant Raising Cardiomyopathy Risk in African Ancestry